Literature DB >> 33087502

Albumin internalizes and inhibits endosomal TLR signaling in leukocytes from patients with decompensated cirrhosis.

Mireia Casulleras1,2, Roger Flores-Costa2, Marta Duran-Güell1,2, José Alcaraz-Quiles2, Silvia Sanz2, Esther Titos2,3, Cristina López-Vicario1,2, Javier Fernández1,4, Raquel Horrillo5, Montserrat Costa5, Pierre de la Grange6, Richard Moreau1,7, Vicente Arroyo1, Joan Clària8,2,3.   

Abstract

Human serum albumin (HSA) is an emerging treatment for preventing excessive systemic inflammation and organ failure(s) in patients with acutely decompensated (AD) cirrhosis. Here, we investigated the molecular mechanisms underlying the immunomodulatory properties of HSA. Administration of HSA to patients with AD cirrhosis with elevated circulating bacterial DNA rich in unmethylated cytosine-phosphate-guanine dideoxynucleotide motifs (CpG-DNA) was associated with reduced plasma cytokine concentrations. In isolated leukocytes, HSA abolished CpG-DNA-induced cytokine expression and release independently of its oncotic and scavenging properties. Similar anti-inflammatory effects were observed with recombinant human albumin. HSA exerted widespread changes on the immune cell transcriptome, specifically in genes related to cytokines and type I interferon responses. Our data revealed that HSA was taken up by leukocytes and internalized in vesicles positively stained with early endosome antigen 1 and colocalized with CpG-DNA in endosomes, where the latter binds to Toll-like receptor 9 (TLR9), its cognate receptor. Furthermore, HSA also inhibited polyinosinic:polycytidylic acid- and lipopolysaccharide-induced interferon regulatory factor 3 phosphorylation and TIR domain-containing adapter-inducing interferon-β-mediated responses, which are exclusive of endosomal TLR3 and TLR4 signaling, respectively. The immunomodulatory actions of HSA did not compromise leukocyte defensive mechanisms such as phagocytosis, efferocytosis, and intracellular reactive oxygen species production. The in vitro immunomodulatory effects of HSA were confirmed in vivo in analbuminemic humanized neonatal Fc receptor transgenic mice. These findings indicate that HSA internalizes in immune cells and modulates their responses through interaction with endosomal TLR signaling, thus providing a mechanism for the benefits of HSA infusions in patients with cirrhosis.
Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33087502     DOI: 10.1126/scitranslmed.aax5135

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  8 in total

1.  A step forward in the choice of fluid for early resuscitation of critically ill patients with cirrhosis.

Authors:  Paolo Angeli
Journal:  Hepatol Int       Date:  2021-07-07       Impact factor: 6.047

Review 2.  Cirrhosis-associated immune dysfunction.

Authors:  Agustín Albillos; Rosa Martin-Mateos; Schalk Van der Merwe; Reiner Wiest; Rajiv Jalan; Melchor Álvarez-Mon
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-10-26       Impact factor: 46.802

3.  Determination of Effective Albumin in Patients With Decompensated Cirrhosis: Clinical and Prognostic Implications.

Authors:  Maurizio Baldassarre; Marina Naldi; Mauro Bernardi; Paolo Caraceni; Giacomo Zaccherini; Michele Bartoletti; Agnese Antognoli; Maristella Laggetta; Martina Gagliardi; Manuel Tufoni; Marco Domenicali; Katja Waterstradt; Paola Paterini; Anna Baldan; Simona Leoni; Manuela Bartolini; Pierluigi Viale; Franco Trevisani
Journal:  Hepatology       Date:  2021-05-26       Impact factor: 17.425

Review 4.  Hypoalbuminemia as Surrogate and Culprit of Infections.

Authors:  Christian J Wiedermann
Journal:  Int J Mol Sci       Date:  2021-04-26       Impact factor: 5.923

Review 5.  Leukocytes, Systemic Inflammation and Immunopathology in Acute-on-Chronic Liver Failure.

Authors:  Mireia Casulleras; Ingrid W Zhang; Cristina López-Vicario; Joan Clària
Journal:  Cells       Date:  2020-12-08       Impact factor: 6.600

Review 6.  Albumin Substitution in Decompensated Liver Cirrhosis: Don't Forget Zinc.

Authors:  Kurt Grüngreiff; Thomas Gottstein; Dirk Reinhold; Claudia A Blindauer
Journal:  Nutrients       Date:  2021-11-10       Impact factor: 5.717

7.  Albumin Lipidomics Reveals Meaningful Compositional Changes in Advanced Cirrhosis and Its Potential to Promote Inflammation Resolution.

Authors:  Mireia Casulleras; Roger Flores-Costa; Marta Duran-Güell; Ingrid W Zhang; Cristina López-Vicario; Anna Curto; Javier Fernández; Vicente Arroyo; Joan Clària
Journal:  Hepatol Commun       Date:  2022-02-18

8.  Insights into innate immune activation via PS-ASO-protein-TLR9 interactions.

Authors:  Adam J Pollak; Luyi Zhao; Timothy A Vickers; Ian J Huggins; Xue-Hai Liang; Stanley T Crooke
Journal:  Nucleic Acids Res       Date:  2022-08-12       Impact factor: 19.160

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.